LCI - Lannett Company, Inc.

NYSE - NYSE Delayed Price. Currency in USD
13.50
-0.25 (-1.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.75
Open13.75
Bid13.45 x 1800
Ask13.80 x 3100
Day's Range13.18 - 13.80
52 Week Range11.90 - 30.35
Volume688,954
Avg. Volume621,023
Market Cap513.192M
Beta1.95
PE Ratio (TTM)11.21
EPS (TTM)1.20
Earnings DateAug 21, 2018 - Aug 27, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.83
Trade prices are not sourced from all markets
  • GlobeNewswire12 days ago

    Detailed Research: Economic Perspectives on A10 Networks, Lannett, Navigant Consulting, EastGroup Properties, Lennox International, and IDEXX Laboratories — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Aug. 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of A10 ...

  • PR Newswire15 days ago

    Lannett Enters Licensing Agreement For Generic Concerta®, Methylphenidate Hydrochloride ER Tablets

    PHILADELPHIA , Aug. 3, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive perpetual licensing agreement with Andor Pharmaceuticals, LLC for Methylphenidate ...

  • PR Newswire26 days ago

    Lannett Announces Multiple Product Launches

    The June product launches include Diclofenac Sodium ER Tablets, Levofloxacin Oral Solution, Memantine Hydrochloride Tablets and Metolazone Tablets.  Total U.S. sales of the combined products were nearly $100 million for the 12 months ended May 2018, according to IMS. Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.  For more information, visit the company's website at www.lannett.com.

  • Lannett sells 2 buildings in Northeast Phila.
    American City Business Journalslast month

    Lannett sells 2 buildings in Northeast Phila.

    Northpoint Development of Riverside, Mo., bought 11501 Roosevelt Blvd., a 230,000-square-foot building on 15.3 acres, and 11601 Roosevelt Blvd., a 441,846-square-foot building on 24 acres, from Lannett. Rich Gorodesky of Colliers International arranged the transaction.  The buildings, which had prior lives as warehouses, had later been converted and used by the IRS for its administrative offices until the agency consolidated and relocated in 2010 to a renovated former post office building across from 30th Street Station in Philadelphia.

  • ACCESSWIRElast month

    Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. WallStEquities.com takes a look at the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others.Under monitoring this morning are four equities: Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK).

  • PR Newswire2 months ago

    Lannett Announces Restructuring Plan Of Cody Laboratories Subsidiary

    PHILADELPHIA , June 29, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost reduction plan of its subsidiary, Cody Laboratories (Cody), a developer and manufacturer ...

  • 3 Top Healthcare Stocks to Buy Right Now
    Motley Fool2 months ago

    3 Top Healthcare Stocks to Buy Right Now

    A cancer-drug developer, generic-drug manufacturer, and medical device kingpin may be just what the doctor ordered.

  • Options Traders Expect Huge Moves in Lannett (LCI) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Lannett (LCI) Stock

    Investors need to pay close attention to Lannett (LCI) stock based on the movements in the options market lately.

  • Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
    Zacks2 months ago

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Lululemon Athletica inc. (NASDAQ: LULU ) stock was ...

  • ACCESSWIRE3 months ago

    Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com scans Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK).

  • PR Newswire3 months ago

    Lannett Receives FDA Approval For Levofloxacin Oral Solution; Imminent Launch Anticipated

    PHILADELPHIA , June 1, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application ...

  • PR Newswire3 months ago

    Lannett Receives FDA Approval For Dronabinol Capsules

    PHILADELPHIA , May 21, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of LCI earnings conference call or presentation 7-May-18 8:30pm GMT

    Q3 2018 Lannett Company Inc Earnings Call

  • ACCESSWIRE3 months ago

    Wired News - Lannett Announced Acquisition of 23 Approved Drug Product Applications from Endo International's Subsidiary

    LONDON, UK / ACCESSWIRE / May 9, 2018 / If you want access to our free research report on Lannett Co., Inc. (NYSE: LCI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LCI as the Company's latest news hit the wire. On May 7, 2018, the Company announced that it has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International PLC (NASDAQ: ENDP) ("Endo") for an upfront payment plus future milestone payments.

  • Associated Press3 months ago

    Lannett: Fiscal 3Q Earnings Snapshot

    The Philadelphia-based company said it had profit of 33 cents per share. Earnings, adjusted for amortization costs and non-recurring costs, were 80 cents per share. The results beat Wall Street expectations. ...

  • PR Newswire3 months ago

    Lannett Announces Fiscal 2018 Third-Quarter Financial Results

    --Adjusted EPS Higher Than Expected; Outlook for Fiscal 2018 Net Sales and Adjusted Profitability Affirmed-- PHILADELPHIA , May 7, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported ...

  • Lannett acquires 23 generic drug products from Endo subsidiary
    American City Business Journals3 months ago

    Lannett acquires 23 generic drug products from Endo subsidiary

    Financial terms of the deal, which includes another product that will soon be submitted for approval from the Food and Drug Administration, were not disclosed.

  • ACCESSWIRE3 months ago

    Lannett Company, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Lannett Company, Inc. (NYSE: LCI ) will be discussing their earnings results in their Q3 Earnings Call to be held on May 7, 2018 at 4:30 PM Eastern Time. To listen ...

  • PR Newswire3 months ago

    Lannett Acquires Portfolio Of Generic Products From Endo International

    Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.  For more information, visit the company's website at www.lannett.com.

  • PR Newswire4 months ago

    Lannett To Participate At Two Investor Conferences In May

    PHILADELPHIA , May 3, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences.  Schedule below: Deutsche Bank 43rd Annual Health Care ...

  • PR Newswire4 months ago

    Lannett To Report Fiscal 2018 Third-Quarter Financial Results, Host Conference Call On Monday, May 7

    PHILADELPHIA , May 2, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 third quarter on Monday, May 7, 2018 , after the market ...

  • Is It Time To Buy Lannett Company Inc (NYSE:LCI) Based Off Its PE Ratio?
    Simply Wall St.4 months ago

    Is It Time To Buy Lannett Company Inc (NYSE:LCI) Based Off Its PE Ratio?

    Lannett Company Inc (NYSE:LCI) is currently trading at a trailing P/E of 12.5x, which is lower than the industry average of 23.4x. While this makes LCI appear like a greatRead More...

  • PR Newswire4 months ago

    Lannett Announces Changes To Board Of Directors

    PHILADELPHIA, Pa., April 30, 2018 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that effective July 1, 2018 current director, Patrick LePore, will become chairman of the board of directors, succeeding Jeffrey Farber, who will remain a member of the board.  The company also said that John C. Chapman has been appointed to the board, effective July 1, 2018, succeeding James Maher, who will step down upon completion of the audit of the fiscal 2018 financial statements. Chapman is a retired audit partner for KPMG, having specialized in providing audit services to large complex multinational pharmaceutical and consumer market companies.  During his tenure at KPMG, he served for six years as a member of the firm's board of directors and for several years as KPMG's global chair of pharmaceuticals and chemicals.  Chapman also served as global lead partner for some of KPMG's largest clients, including Pfizer, Hoechst and PepsiCo, among others.  Chapman, a certified public accountant (CPA), earned a bachelor of business administration in accounting practice degree from Pace University, New York.

  • PR Newswire4 months ago

    Lannett Names Maureen Cavanaugh Senior Vice President And Chief Commercial Operations Officer

    --Company Re-aligns Management Responsibilities-- PHILADELPHIA , April 20, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Maureen M. Cavanaugh to the newly created ...